Disc Medicine, Inc.

NasdaqGM IRON

Disc Medicine, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -124.71 M

Disc Medicine, Inc. EBITDA is USD -124.71 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -50.96% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Disc Medicine, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -82.61 M, a -64.95% change year over year.
Disc Medicine, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -50.08 M, a -12.39% change year over year.
Disc Medicine, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -44.56 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: IRON

Disc Medicine, Inc.

CEO	Dr. John D. Quisel Esq., J.D., Ph.D.
IPO Date	Aug. 12, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	82
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Key trends

Past 5 years